DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Idronoxil is an investigational drug.
There have been 6 clinical trials for Idronoxil. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Peritoneal Neoplasms, and Fallopian Tube Neoplasms. The leading clinical trial sponsors are Noxopharm Limited, Yale University, and National Cancer Institute (NCI).
Recent Clinical Trials for Idronoxil
|A Study of Safety and Tolerability of NOX66 in Healthy Volunteers||Noxopharm Limited||Phase 1|
|Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer||Noxopharm Limited||Phase 1|
|Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer||Royal North Shore Hospital||Phase 1|